Cynosure Group’s Corcept Therapeutics CORT Stock Holding History

Cynosure Group’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-6,015	Closed	-$209K	–	264
2025 Q4	$209K	Buy	+6,015	New	+$472K	0.02%	399

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Cynosure Group's CORT Position: Q1 2026 in Review

Cynosure Group sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 6,015 shares — an estimated $209K sold.

Cynosure Group first reported a position in CORT in Q4 2025 and held it in 1 quarter. The position peaked at $209K in Q4 2025. 352 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

Cynosure Group reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
Cynosure Group sold 6,015 Corcept Therapeutics shares in Q1 2026, an estimated $209K.
Cynosure Group first reported a position in Corcept Therapeutics in Q4 2025 and held it in 1 quarter.
Cynosure Group's Corcept Therapeutics position peaked at $209K in Q4 2025.
352 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Cynosure Group's 13F filing for Q1 2026, filed 14 May 2026.